Medical Education Library

SGLT-2 Inhibition in the Kidney: Changing Paradigms in the Treatment of Type 2 Diabetes Mellitus

This INDUSTRY DIRECT supplement to The Journal of Family Practice is brought to you by Janssen.

 

The pathophysiology of type 2 diabetes mellitus (T2DM) is recognized as a complex interplay of several defects. Of these, insulin resistance in muscle and liver and impaired insulin secretion due to pancreatic b-cell dysfunction are the most widely recognized as playing central roles.1-3 Other defects include increased glucagon secretion by the pancreatic islet a-cells, increased hepatic glucose production, decreased glucose uptake by muscle, decreased incretin effect in the gastrointestinal tract, and increased adipocyte lipolysis.

Recommended Reading

Luteal-phase antidepressant an option in recalcitrant PMS, PMDD
MDedge Family Medicine
Legal battle over contraception mandate rages on
MDedge Family Medicine
Smoking rate among people with mental illness shows negligible decline
MDedge Family Medicine
Mediterranean diet plus olive oil kept diabetes away
MDedge Family Medicine
The future of meaningful use
MDedge Family Medicine
Triple-antiviral therapy achieves 94% response without interferon, ribavirin
MDedge Family Medicine
CMS: Spending on physician services grew faster in 2012
MDedge Family Medicine
Postpartum care after gestational diabetes is preconception care as well
MDedge Family Medicine
Smoking cessation maintained with varenicline plus CBT
MDedge Family Medicine
Bupropion-varenicline combo gave harder kick to smoking habits
MDedge Family Medicine